Healthcare provider profile · identity verified

David C Bauman, MD

Family Practice · MURFREESBORO, TN · NPI 1518944784

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	455	146
Amlodipine Besylate	Amlodipine Besylate	315	92
Losartan Potassium	Losartan Potassium	261	84
Levothyroxine Sodium	Levothyroxine Sodium	256	68
Lisinopril	Lisinopril	225	67
Omeprazole	Omeprazole	207	59
Hydrochlorothiazide	Hydrochlorothiazide	182	55
Rosuvastatin Calcium	Rosuvastatin Calcium	175	51
Metformin Hcl	Metformin Hcl	151	46
Pantoprazole Sodium	Pantoprazole Sodium	145	51
Simvastatin	Simvastatin	136	33
Tamsulosin Hcl	Tamsulosin Hcl	129	44
Metoprolol Succinate	Metoprolol Succinate	128	37
Albuterol Sulfate Hfa	Albuterol Sulfate	108	33
Duloxetine Hcl	Duloxetine Hcl	103	26
Metformin Hcl Er	Metformin Hcl	97	30
Escitalopram Oxalate	Escitalopram Oxalate	96	26
Gabapentin	Gabapentin	96	23
Furosemide	Furosemide	90	33
Fluticasone Propionate	Fluticasone Propionate	88	34
Potassium Chloride	Potassium Chloride	86	29
Sertraline Hcl	Sertraline Hcl	85	25
Trazodone Hcl	Trazodone Hcl	84	29
Famotidine	Famotidine	82	26
Carvedilol	Carvedilol	78	27
Pravastatin Sodium	Pravastatin Sodium	74	23
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	63	20
Metoprolol Tartrate	Metoprolol Tartrate	58	20
Spironolactone	Spironolactone	58	23
Clopidogrel	Clopidogrel Bisulfate	56	20
Eliquis	Apixaban	56	11
Allopurinol	Allopurinol	55	18
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	54	14
Alendronate Sodium	Alendronate Sodium	53	17
Meloxicam	Meloxicam	51	16
Trulicity	Dulaglutide	47	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	46	14
Pregabalin	Pregabalin	44	suppressed
Citalopram Hbr	Citalopram Hydrobromide	43	12
Diclofenac Sodium	Diclofenac Sodium	40	15
Jardiance	Empagliflozin	40	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	38	suppressed
Prednisone	Prednisone	38	19
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	37	suppressed
Ozempic	Semaglutide	34	suppressed
Chlorthalidone	Chlorthalidone	33	11
Valsartan	Valsartan	33	suppressed
Montelukast Sodium	Montelukast Sodium	32	12
Propranolol Hcl	Propranolol Hcl	31	suppressed
Xarelto	Rivaroxaban	31	suppressed
Glipizide	Glipizide	30	12
Fluoxetine Hcl	Fluoxetine Hcl	29	suppressed
Synthroid	Levothyroxine Sodium	29	suppressed
Bupropion Xl	Bupropion Hcl	28	11
Primidone	Primidone	27	suppressed
Valacyclovir	Valacyclovir Hcl	27	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	26	suppressed
Azelastine Hcl	Azelastine Hcl	26	suppressed
Buspirone Hcl	Buspirone Hcl	25	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	25	17
Mirtazapine	Mirtazapine	25	suppressed
Benazepril Hcl	Benazepril Hcl	24	suppressed
Ezetimibe	Ezetimibe	24	suppressed
Glimepiride	Glimepiride	24	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	24	suppressed
Celecoxib	Celecoxib	23	suppressed
Spiriva Handihaler	Tiotropium Bromide	23	suppressed
Dexlansoprazole Dr	Dexlansoprazole	22	suppressed
Glipizide Er	Glipizide	21	suppressed
Hydralazine Hcl	Hydralazine Hcl	20	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	20	suppressed
Acyclovir	Acyclovir	19	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	19	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	19	suppressed
Farxiga	Dapagliflozin Propanediol	18	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	18	suppressed
Mounjaro	Tirzepatide	18	suppressed
Tizanidine Hcl	Tizanidine Hcl	18	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	18	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	17	suppressed
Alprazolam	Alprazolam	16	suppressed
Atenolol	Atenolol	16	suppressed
Finasteride	Finasteride	16	suppressed
Ketoconazole	Ketoconazole	16	suppressed
Loperamide	Loperamide Hcl	16	suppressed
Novolog Flexpen	Insulin Aspart	16	suppressed
Sildenafil Citrate	Sildenafil Citrate	16	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	15	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	15	suppressed
Irbesartan	Irbesartan	15	suppressed
Naproxen	Naproxen	15	suppressed
Ramipril	Ramipril	15	suppressed
Torsemide	Torsemide	15	suppressed
Doxepin Hcl	Doxepin Hcl	14	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	14	suppressed
Nifedipine Er	Nifedipine	14	suppressed
Zolpidem Tartrate Er	Zolpidem Tartrate	14	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	13	11
Pioglitazone Hcl	Pioglitazone Hcl	13	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	13	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	13	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	12	suppressed
Clonidine Hcl	Clonidine Hcl	12	suppressed
Entresto	Sacubitril/Valsartan	12	suppressed
Fenofibrate	Fenofibrate	12	suppressed
Humalog Kwikpen U-100	Insulin Lispro	12	suppressed
Insulin Syringe	Syring-Needl,disp,insul,0.3 Ml	12	suppressed
Memantine Hcl	Memantine Hcl	12	suppressed
Methylprednisolone	Methylprednisolone	12	11
Rizatriptan	Rizatriptan Benzoate	12	suppressed
Cephalexin	Cephalexin	11	suppressed
Enalapril Maleate	Enalapril Maleate	11	suppressed
Paroxetine Hcl	Paroxetine Hcl	11	suppressed
Terazosin Hcl	Terazosin Hcl	11	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error